Medivation, Astellas XTANDI available to those previously treated with Docetaxel Medivation and Astellas Pharma announced the availability of XTANDI capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI was approved by the U.S. FDA on Aug. 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.